Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players
April 30, 2021
- Shionogi, InveniAI Ink Drug Discovery Collaboration
April 30, 2021
- 300 Million Yen Fine Sought for Toho Too, Court Decision Due June 2: Bid-Rigging Trial
April 30, 2021
- Takeda’s Mobocertinib Gets FDA’s Priority Review for EGFR Exon 20-Mutant NSCLC
April 30, 2021
- Pfizer Japan Posts 251 Billion Yen Sales in FY2020 after Upjohn Spinoff
April 30, 2021
- Amgen Files KRAS Inhibitor Sotorasib in Japan for NSCLC
April 30, 2021
- Court’s Settlement Offer on Opdivo Royalty Dispute Fails
April 28, 2021
- Prosecutors Seek 300 Million Yen Fine for Suzuken, Jail Terms for Employees: Bid-Rigging Trial
April 28, 2021
- Takeda, Eisai, Chemiphar Ran Early Retirement Programs over Past Year: Survey
April 28, 2021
- Boehringer’s Japan Pharma Sales Rise 3.1% in 2020 on Ofev, Jardiance
April 28, 2021
- Daiichi Sankyo Sales Slip in FY2020 as Price Cuts, Deal Termination Weigh
April 28, 2021
- Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold
April 28, 2021
- Daiichi Sankyo Gets Brazil, South Korea Rights to Esperion’s Hypercholesterolemia Drug
April 28, 2021
- AbbVie Files Maviret for Use in Children Age 3 Plus
April 28, 2021
- Nihon Generic Recalling Metformin Products over Carcinogen Risks
April 27, 2021
- SymBio’s Brincidofovir Gets FDA’s Fast-Track Status
April 27, 2021
- Kyorin Grabs Distribution Rights to MSD’s Cough Medicine in Japan
April 27, 2021
- Lilly, Daiichi Sankyo Roll Out Migraine Drug Emgality in Japan
April 27, 2021
- Novartis Offering Voluntary Redundancy for 3rd Consecutive Year, Targets Sales & Medical across Therapeutic Areas
April 27, 2021
- NanoCarrier, Axcelead Forge JV to Develop mRNA-Driven Articular Cartilage Drug
April 27, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…